Oxford treats first local patients in Quell’s autoimmune cell-therapy trial
Oxford’s Experimental Medicine Clinical Research Facility has recruited two patients to the CHILL trial of Quell Therapeutics’ engineered regulatory T-cell therapy for severe autoimmune diseases, including rheumatoid arthritis and systemic sclerosis. The first participant was treated at Leeds; Oxford says its first patient tolerated the dose and went home the following day.
Bottom line — CHILL is a Phase 1/2 trial planned across 3 countries, with 10–16 participants.
Go deeper 5
-
Oxford says this is its first engineered cell-therapy trial for autoimmune disease outside haematology and oncology.
-
The therapy uses engineered regulatory T cells designed to reach inflamed tissue and reduce harmful immune activity, according to Oxford University Hospitals.
-
The Oxford team said it was the second site globally to administer the treatment.
-
The National Institute for Health and Care Research says the UK’s first site activated the trial in 113 days; three UK sites are open, with four more expected.
-
The NIHR says the first clinical findings are expected in the first quarter of 2027.
techwithnani.blogspo…